Search PubMed⌕ Search

Biomedical subjects

M Moulds

Publications and source records attributed to M Moulds.

At least 19 recordsLinked to original sources

Reactivity of FDA-approved anti-D reagents with partial D red blood cells.

Individuals whose RBCs are characterized as having a partial D phenotype may make anti-D if exposed to normal D+ RBCs; thus it is desirable that they be typed as D- should they require blood transfusion or Rh immune globulin (RhIG) prophylaxis. Further, use of different anti-D reagents by blood centers and transfusion services can account for FDA-reportable errors. For this study, anti- D reagents for use in tube tests were obtained from three U.S. manufacturers. They included three examples of IgM monoclonal anti-D blended with monoclonal IgG anti-D, one IgM monoclonal anti-D blended with polyclonal IgG anti-D, and two reagents formulated with human anti-D in a high-protein diluent. One anti- D formulated for use by gel column technology was also tested. Direct agglutination tests by tube or gel were strongly positive (scores 9-12), with partial D RBCs of types DII, DIIIa, DIIIb, and DIVa. No reagent anti-D caused direct agglutination of DVI type 1, DVI type 2, or DFR phenotype RBCs. One tube anti-D reagent formulated with an IgM monoclonal anti-D plus a polyclonal IgG anti-D failed to cause direct agglutination of DVa, DBT, and R(0)(Har) RBCs, while DVa RBCs reacted weakly with two high-protein reagents formulated with human IgG anti-D. In contrast, the anti-D used by gel column technology was strongly reactive (score 11) with DVa, DBT, and R(0)(Har) RBCs. The single monoclonal IgM-polyclonal IgG blended anti-D and the two high-protein reagents were also the only reagents that failed to react with R(0)(Har) RBCs by the IAT. Elimination of the test for weak D on all patient samples, using currently available FDA-licensed reagents, will ensure that partial D category VI (DVI) patients will type as D- for the purpose of RhIG prophylaxis and blood transfusion. However, RBCs of other partial D phenotypes will be classified as D+ in direct agglutination tests with some, if not all, currently available reagents. Testing donors for weak expression of D continues to be required, albeit that Rh alloimmunization by RBCs with a weak or partial D phenotype is uncommon. Further, because of differences in performance characteristics among FDA-approved reagents, conflicts between donor center D typing and transfusion service confirmatory test results are inevitable.

Blood Grouping and Crossmatching↗

Direct evidence for the existence of Miltenberger antigen.

The Miltenberger (Mi) subsystem, which originally consisted of four phenotypes, now has 11 phenotypes. The antigens of this subsystem belong to the MNS blood group system. The Mia antigen has been reported to be present on red blood cells with several Miltenberger phenotypes, namely: Mi.I, Mi.II, Mi.III, Mi.IV, Mi.VI and Mi.X. However, the existence of the Mia antigen as a separate entity has been in question and difficult to prove with polyclonal reagents. We report the first monoclonal anti-Mia (GAMA210), whose epitope is TNDKHKRD or QTNDMHKR, and thereby confirm the existence of the Mia antigen.

Animals↗

Treating acute stress disorder: an evaluation of cognitive behavior therapy and supportive counseling techniques.

OBJECTIVE: Acute stress disorder permits an early identification of trauma survivors who are at risk of developing chronic posttraumatic stress disorder (PTSD). This study aimed to prevent PTSD by an early provision of cognitive behavior therapy. Specifically, this study indexed the relative efficacy of prolonged exposure and anxiety management in the treatment of acute stress disorder. METHOD: Forty-five civilian trauma survivors with acute stress disorder were given five sessions of 1) prolonged exposure (N = 14), 2) a combination of prolonged exposure and anxiety management (N = 15), or 3) supportive counseling (N = 16) within 2 weeks of their trauma. Forty-one trauma survivors were assessed at the 6-month follow-up. RESULTS: Fewer patients with prolonged exposure (14%, N = 2 of 14) and prolonged exposure plus anxiety management (20%, N = 3 of 15) than supportive counseling (56%, N = 9 of 16) met the criteria for PTSD after treatment. There were also fewer cases of PTSD in the prolonged exposure group (15%, N = 2 of 13) and the prolonged exposure plus anxiety management group (23%, N = 3 of 13) than in the supportive counseling group (67%, N = 10 of 15) 6 months after the trauma. Chronic PTSD in the supportive counseling condition was characterized by greater avoidance behaviors than in the prolonged exposure condition or the prolonged exposure plus anxiety management condition. CONCLUSIONS: These findings suggest that PTSD can be effectively prevented with an early provision of cognitive behavior therapy and that prolonged exposure may be the most critical component in the treatment of acute stress disorder.

Acute Disease↗

Anti-Lu9: the finding of the second example after 25 years.

The first and only reported example of anti-Lu9 (an antibody directed at a low-incidence antigen in the Lutheran blood group system and allelic to the high-incidence antigen Lu6) was described in 1973 in the serum of a white female, Mrs. Mull. Her serum also contained anti-Lu1 (-Lua), and subsequently, an anti-HLA-B7 (-Bga) was identified. We report the second example of anti-Lu9 in a white male (GR), found 25 years later. The GR serum was reactive in the indirect antiglobulin test with Lu:-1,2,6,9 antibody-screening red blood cells (RBCs) using either a low-ionic-saline additive solution or polyethylene glycol for enhancement. Lu:6,9 RBCs were reactive with the serum when ficin- or EDTA/glycine-acid-treated, but nonreactive when trypsin- or a-chymotrypsin-treated. Six known examples of Lu:9 RBCs were reactive with the GR serum. His serum did not contain anti-Lua, anti-HLA-B7 (-Bga) or antibodies to 34 low-incidence antigens tested. We have identified the second example of anti-Lu9 that was likely stimulated by transfusion. Because only one of 200 donors was found to be Lu:9, our study suggests that the incidence of the Lu9 antigen may be less than originally thought.

Journal Article↗

A Gly565-->Ala substitution in human erythroid band 3 accounts for the Wu blood group polymorphism.

BACKGROUND: Reports published in 1976 and 1980 described the low-incidence red cell antigen Wu. Distinction of Wu from all other known low-incidence antigens and from the ABO, Rh, Lutheran, Duffy, Kidd, P, and X-linked blood group systems allowed Wu to be placed in the International Society of Blood Transfusion's 700 series, designated as 700013. Recently, a blood donor apparently homozygous for Wu has been identified. This report documents the serologic and molecular findings of samples from this individual and the members of his family. STUDY DESIGN AND METHODS: Blood samples from 26 members of a kindred of Dutch descent segregating for Wu were collected and analyzed. Red cells were subjected to titration and enzymatic tests, while DNA was analyzed by polyacrylamide gel electrophoresis for single-strand conformational polymorphism (SSCP) and nucleotide differences by DNA sequencing. RESULTS: Serologic investigations conducted on red cells of the propositus and two of his siblings consistently revealed higher titers with various sera containing anti-Wu than did cells from their parents or children. Treatment of intact red cells with alpha-chymotrypsin completely abolished Wu recognition. Because erythroid band 3 is cleaved by alpha-chymotrypsin, the possible relationship between Wu and AE1 (the gene controlling erythroid band 3 expression) was investigated by molecular methods. SSCP analysis of DNA revealed that all Wu+ family members exhibited a mobility shift in exon 14 of AE1. The nature of the SSCP was defined by DNA sequencing as a G-->C mutation that resulted in a Gly565-->Ala substitution in human erythroid band 3. CONCLUSIONS: Three members of the kindred are homozygous for the low-incidence red cell antigen Wu. A G-->C mutation in AE1 gives rise to a Gly565-->Ala substitution in band 3, thereby accounting for the Wu red cell polymorphism. In light of these findings, the International Society of Blood Transfusion Working Party has provisionally assigned Wu to the Diego blood group system (designated 010009 or D19).

Alanine↗

Comparison of affinity column technology and LISS tube tests.

Proteins G and A coated on agarose have been extensively used in affinity chromatography. Protein G will bind to all four subclasses of human IgG and protein A to the subclasses IgG1, IgG2, and IgG4. This IgG binding ability of protein G and protein A has been used in a red cell affinity column technology developed for the detection and identification of IgG red cell antibodies. When serum or plasma is incubated in a microcolumn with red blood cells (RBCs) that express the appropriate antigens, the antibodies become attached to the RBC surface. When the microcolumns are centrifuged, the RBCs pass through a viscous barrier into an active matrix containing proteins G and A. Positive tests adhere at the top of the gel and negative tests pass through, settling to the bottom. This study was undertaken to compare affinity column technology with low-ionic saline solution (LISS) tube tests in a reference laboratory setting. Over a 1-year period, 314 samples were tested in parallel by affinity column technology and by LISS tube technique. Both methods detected antibodies directed at common RBC antigens, high-incidence and low-incidence RBC antigens, and warm-reacting autoantibodies. IgM antibodies were not detected by affinity column technology. Affinity column technology compares favorably with the LISS tube technique for IgG antibody detection and identification.

Journal Article↗

A 'new' low-incidence red cell antigen, WARR: unique to Native Americans?

Investigation of a mild case of hemolytic disease of the newborn has led to recognition of a 'new' low-incidence red cell antigen, WARR (ISBT No. 700.55). Data gleaned from two kindreds, both with Native American heritage, exclude WARR from the MNS, Lutheran, Lewis, Duffy, Kidd, Xg, Chido/Rodgers, Kx and Gerbich blood group systems. Serologic or genetic evidence suggests it is not part of the Kell or Yt systems.

Blood Group Antigens↗

Demonstration by the monoclonal antibody-specific immobilization of erythrocyte antigens assay that a new red cell antigen belongs to the Kell blood group system.

BACKGROUND: The Kell blood group system comprises 21 antigens residing on a red cell membrane glycoprotein of apparent M(r) 93,000. STUDY DESIGN AND METHODS: Serologic techniques were used to identify a new red cell antigen. The monoclonal antibody-specific immobilization of erythrocyte antigens (MAIEA) assay was used to identify the red cell membrane component carrying that antigen. RESULTS: A new high-frequency red cell antigen was identified and provisionally named RAZ. RAZ is absent from K.o red cells and from red cells treated with 2-amino-ethylisothiouronium bromide and is expressed weakly on McLeod phenotype cells. It differs from all other Kell system antigens, and no depression of other Kell system antigens on RAZ+ red cells was noticed. The RAZ antigen was shown by the MAIEA assay to be located on the Kell glycoprotein. CONCLUSION: RAZ is a new high-frequency antigen located on the Kell glycoprotein. The MAIEA assay is a very effective method of demonstrating the membrane structure carrying a red cell antigen.

Antibodies, Monoclonal↗

Autoimmune hemolysis following transfusion: a mimicking autoanti-D in a D- patient with alloanti-D.

An 80-year-old group O, D- (rr) female with anti-C, -D, -E, and -Fya received four units of crossmatch-compatible red blood cells (RBCs). The direct antiglobulin test (DAT) was negative. Two weeks later, jaundice, dark urine, a 16% drop in hematocrit (Hct), a 20% reticulocyte count, and absent haptoglobin occurred. During the next month, her DAT was positive with anti-IgG and -C3d. Acid eluates, which repeatedly showed anti-D specificity, were nonreactive with enzyme-treated D- RBCs. Adsorption with D- RBCs reduced reactivity. An eluate from the adsorbing D- RBCs was nonreactive with D+ KBCs. These findings suggest an autoantibody mimicking alloanti-D. The patient was treated with prednisone and was transfused with group O, D- (rr), K-, Fy(a-) RBCs. Four months later, the Hct was stable. One year later, the DAT remained positive and the eluate demonstrated a panagglutinin.

Journal Article↗

Studies on the structures of the Tm, Sj, M1, Can, Sext and Hu blood group antigens.

The Glycophorins (GPs = sialoglycoproteins) in erythrocyte membranes from various Black individuals, some of which exhibit the M1, Can, Sj, Tm, Sext and/or Hu antigens, and several Caucasian donors, including pooled fetal red cells, were studied. Using agglutination inhibition assays with GP fractions, GP fragments and chemically modified GPs as well as trypsin treatment of intact red cells, the antigens defined by anti-M1, anti-M+M1, anti-Can and anti-Tm sera were found to be located on the N-terminal tryptic peptide (T2, residues 1-31) of the major GP (GP A = MN sialoglycoprotein). Evidence was obtained that the N-terminal amino-acid residue, NeuNAc and/or (a) different sugar residue(s) are involved in the antigens. Amino-acid sequence and composition analyses excluded an amino-acid exchange within the N-terminal region (residues 1-31) of GP A. Carbohydrate analyses revealed the attachment of GlcNAc residues (up to about five, dependent on the strength of the above-mentioned antigens) to O-glycosidically linked oligosaccharides within the N-terminal portion (residues 1-31) of GP A. As judged from the carbohydrate compositions of peptides, the alteration of the O-glycosidic oligosaccharides is associated with a slight increase of the Gal and Fuc contents and a slight decrease of the NeuNAc level. Analyses of small, secondary cyanogen bromide and V8 proteinase peptides from the N-terminal region of GP A from Blacks, Caucasians and Caucasian fetal cells suggest that the variable attachment of small quantities of GlcNAc (about 0.03 to about 0.2 residues per peptide molecule) accounts, at least in part, for the polymorphisms detected by anti-Can and the original anti-Tm (serum Sheerin). Remarkably, the GlcNAc-containing O-glycosidic oligosaccharides occur only in small quantities, or not all at, within the positions 32-61 of GP A and the glycosylated domains of GP B and GP C.(ABSTRACT TRUNCATED AT 400 WORDS)

Acetylglucosamine↗

Genetic evidence that the gene controlling Aub is located on chromosome 19.

DNA from a series of families segregating for Aub was analyzed with a genomic DNA probe which defines a Bg1 I polymorphism for apolipoprotein C II (APOC2). The investigation revealed that the gene for Aub is closely linked to APOC2 (z = 8.43 at theta = 0.00) for paternal and maternal meioses combined, to LW (z = 3.61 at theta = 0.00) in paternal meioses and less closely linked to SE (z = 3.10 at theta = 0.09) for combined paternal and maternal meioses. Therefore, we propose a chromosome 19 location for the Aub gene.

Blood Group Antigens↗

A low-incidence red cell antigen JAL associated with two unusual Rh gene complexes.

A multilaboratory investigation during several years has identified a low incidence antigen JAL on the red cells of 7 propositi. JAL appears to be associated with two unusual Rh complexes, one of which produces a depressed C antigen and the other a depressed c antigen. Family studies strongly suggest that the JAL antigen is encoded by the RH locus. Anti-JAL has been implicated in haemolytic disease of the newborn and is thus considered to be a clinically significant antibody.

Female↗

Du phenotyping by the rosette technique when the direct antiglobulin test is positive.

The rosette technique provides a simple rapid and accurate procedure for Du phenotyping of red blood cells (RBCs) with a positive direct antiglobulin test (DAT) due to antibodies other than those of the Rh system. We used Sebring and Polesky's rosette technique to test RBCs with positive DATs. Characteristic microscopic agglutination was observed for the Du phenotype which was different from the mixed-field agglutination seen as positive rosettes in feto-maternal hemorrhage (FMH). The microscopic "starry-sky" pattern typical for FMH-positive rosettes is easily differentiated from the uniform agglutination produced by the D phenotype. The rosette technique was performed on 202 Rh negative cord RBCs out of 4815 cord cells with a positive DAT. Parallel testing for Du by the chloroquine elution and antihuman globulin (AHG) test was done on 67 of the 202 cases. Four Du RBCs that were identified by the rosette technique were confirmed by the chloroquine Du technique The rosette technique proved to be time saving and as sensitive as the routinely performed elution technique for removal of antibodies followed by the AHG Du test.

Journal Article↗